Company / Named in our posts
TuHURA Biosciences, Inc..
Follow TuHURA Biosciences, Inc.Clinical-stage immuno-oncology company developing personalized cancer vaccine product candidates designed to overcome resistance to immunotherapies.[1]
02Deals
Deals on Carrywatch
Every deal that names TuHURA Biosciences, Inc., and its role in each.
TuHURA Biosciences, Inc. / Kineta, Inc.
TuHURA Biosciences completes Kineta acquisition, adding a cancer drug candidate
See deal detailsKintara Therapeutics, Inc. / TuHURA Biosciences, Inc.
Kintara Therapeutics and TuHURA Biosciences complete merger transaction
See deal detailsDeal Web
TuHURA Biosciences, Inc. and 1 firm it shares a posted deal with, and the path to any other firm.
Financials
6 fiscal years of figures as TuHURA Biosciences, Inc. reported them.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01Exhibit 99.3 — TuHURA Biosciences, Inc. and Subsidiary Condensed Consolidated Financial Statements
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
- 02SEC EDGAR company record for TuHURA Biosciences, Inc.
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming TuHURA Biosciences, Inc.:
- P01
- P02